Physician profile
Kris Ton
NPI 1205860988
$601.18
in general payments reported to CMS, 2019-2025
13 companies · $466 in 2025
The $466 reported for 2025 was more than what 79% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.19 · 2024: $117 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $117.39 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $67.65 | 2025 | Imfinzi |
| Abbvie INC. | $64.48 | 2023-2025 | |
| Daiichi Sankyo INC. | $54.02 | 2025 | Datroway, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $50.56 | 2025 | Fruzaqla, Iclusig |
| Puma Biotechnology, INC. | $46.65 | 2025 | |
| Genmab U.S., INC. | $32.65 | 2025 | Epkinly |
| Exelixis INC. | $32.48 | 2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $31.27 | 2025 | |
| Karyopharm Therapeutics INC. | $28.22 | 2025 | Xpovio |
| Aveo Pharmaceuticals, INC. | $27.12 | 2025 | |
| Merck Sharp & Dohme LLC | $26.71 | 2025 | Keytruda |
| Incyte Corporation | $21.98 | 2025 | Zynyz, Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Ton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.